<< Previous Message | Next Message >>
From:Diana Goodwin <slipper@net-gate.com> (by way of histonet)
To:histonet <histonet@magicnet.net>
Content-Type:text/plain; charset="us-ascii"

Hello, Histoland!

I just attended a seminar sponsored by Dako entitled "Breast Cancer
Solutions"  which introduced the Herceptest for Her2.  There was an
article about the test and its affiliattion with Herceptin therapy as
approved by the FDA in September.

I would like to know the thoughts of the community regarding the
Herceptest vs. standard cerb-2 IHC testing.  Will you switch
methodologies based on FDA approval?  What will this mean for all of the
other IHC markers, none of which are FDA approved?  Will FDA approval
become an issue for reinbursement of IHC testing?  Will clinicians
prescribe Herceptin only if a Herceptest is used, and do they have the
option to accept other Her-2 testing results as the basis for
prescribing Herceptin?

Looking forward to hearing your views.

Diana Goodwin, HT
Trenton, NJ

<< Previous Message | Next Message >>